Intervention Review

Galantamine for Alzheimer's disease and mild cognitive impairment

  1. Clement Loy1,*,
  2. Lon Schneider2

Editorial Group: Cochrane Dementia and Cognitive Improvement Group

Published Online: 21 JAN 2009

Assessed as up-to-date: 15 NOV 2005

DOI: 10.1002/14651858.CD001747.pub3

Database Title

Additional Information

How to Cite

Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD001747. DOI: 10.1002/14651858.CD001747.pub3.

Author Information

  1. 1

    Garvan Institute of Medical Research, Level 7, Darlinghurst, NSW, Australia

  2. 2

    University of Southern California Keck School of Medicine, Los Angeles, CA, USA

*Clement Loy, Level 7, Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia. clementloy@fastmail.fm.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 21 JAN 2009

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Summary (60K)Standard (436K)Full (1122K)

  1. Current Version

    Galantamine for Alzheimer's disease and mild cognitive impairment

    Clement Loy and Lon Schneider

    Article first published online: 21 JAN 2009 | DOI: 10.1002/14651858.CD001747.pub3

Previous versions of this article and their online publication dates

  1. Version 2

    Galantamine for Alzheimer's disease

    C Loy and L Schneider

    Article first published online: 19 OCT 2005 | DOI: 10.1002/14651858.CD001747.pub2

  2. Version 1

    Galantamine for dementia due to Alzheimer's disease

    J Olin and L Schneider

    Article first published online: 19 JUL 2004 | DOI: 10.1002/14651858.CD001747

View Full Article (HTML) Summary (60K)Standard (436K)Full (1122K)